Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA trial Journal Article

Authors: Sonnenblick, A.; Bailey, A.; Uziely, B.; Untch, M.; Smith, I.; Gianni, L.; Baselga, J.; Jackisch, C.; Cameron, D.; Bell, R.; Zardavas, D.; Al-Sakaff, N.; Gelber, R. D.; Dowsett, M.; Leyland-Jones, B.; Piccart-Gebhart, M. J.; Evandro de Azambuja, E.
Article Title: Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA trial
Abstract: Background/Aim: This study sought to determine whether an autoimmune background could identify patients with HER2-positive early breast cancer (EBC) who derive differential benefit from primary adjuvant trastuzumab-based therapy. Patients and Methods: HERA is an international randomized trial of 5,102 women with HER2-positive EBC, who were enrolled to either receive adjuvant trastuzumab or not. In this exploratory analysis, the interaction between autoimmune history and the magnitude of trastuzumab benefit was evaluated. Results: A total of 5,099 patients were included in the current analysis. Among them, 325 patients (6.4%) had autoimmune disease history, 295 of whom had active disease. Patients were randomly assigned to trastuzumab or no-trastuzumab groups. Similar reductions in the risk of events in patients with and without autoimmune history were observed (interaction p=0.95 for disease-free survival, and p=0.62 for overall survival). Conclusion: No evidence of a differential benefit from trastuzumab in patients with a medical history of autoimmune disease was found. © International Institute of Anticancer Research. All rights reserved.
Keywords: breast cancer; autoimmunity; trastuzumab; her2
Journal Title: Anticancer Research
Volume: 39
Issue: 2
ISSN: 0250-7005
Publisher: International Institute of Anticancer Research  
Date Published: 2019-02-01
Start Page: 797
End Page: 802
Language: English
DOI: 10.21873/anticanres.13177
PUBMED: 30711959
PROVIDER: scopus
Notes: Article -- Export Date: 1 March 2019 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Jose T Baselga
    395 Baselga